Neuraly

company

About

Neuraly is a startup biotech company.

  • 11 - 50

Details

Last Funding Type
Series A
Last Funding Money Raised
$36M
Industries
Biotechnology,Health Care
Founded date
Jan 1, 2016
Number Of Employee
11 - 50
Operating Status
Active

Neuraly, a startup biotech company, was formed in 2016 following foundational research by world class neuroscientists led by Ted Dawson, M.D., Ph.D., Leonard and Madlyn Abramson Professor in Neurodegenerative Diseases and Director of the Institute for Cell Engineering at the Johns Hopkins School of Medicine. Following the acquisition of exclusive licenses to patents covering the composition of matter and methods of use, research supporting the development of NLY01 was recently published in Nature Medicine1. These data demonstrated the critical role of the glial compartment of the neural tissue in the pathogenesis of neurodegenerative diseases such as Parkinson's and Alzheimer's diseases.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$36M
Neuraly has raised a total of $36M in funding over 2 rounds. Their latest funding was raised on Jul 18, 2018 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jul 18, 2018 Series A $36M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Neuraly is funded by 1 investors. Geon Investment are the most recent investors.
Investor Name Lead Investor Funding Round
Geon Investment Series A